(Q43080336)

13 November 2017

0 references

Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-analysis (English)

1 reference

13 November 2017

1 reference

cardiovascular disease

1 reference

1 reference

Naveed Younis

1

1 reference

13 November 2017

Steven Williams

series ordinal

2

1 reference

13 November 2017

Basil Ammori

series ordinal

3

1 reference

13 November 2017

Handrean Soran

series ordinal

4

1 reference

13 November 2017

language of work or name

English

0 references

publication date

1 June 2010

1 reference

Expert Opinion on Pharmacotherapy

13 November 2017

1 reference

13 November 2017

11

1 reference

13 November 2017

9

1 reference

13 November 2017

1459-1466

1 reference

Impact of deprivation on cardiovascular risk factors in people with diabetes: an observational study

13 November 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656561003792538

Projecting the future diabetes population size and related costs for the U.S.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003792538

Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003792538

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003792538

Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003792538

Prevalence and mortality of acute myocardial infarction in patients with diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003792538

Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003792538

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003792538

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003792538

Diabetes mellitus: a hypercoagulable state

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003792538

Diabetes mellitus as a prothrombotic condition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003792538

Diabetic dyslipidaemia: from basic research to clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003792538

Glycation as an atherogenic modification of LDL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003792538

Aspirin and clopidogrel: efficacy and resistance in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003792538

The presence of coronary artery disease increases platelet-dependent thrombosis in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003792538

The platelet in diabetes: focus on prevention of ischemic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003792538

Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003792538

Impact of P2Y(12) inhibitory effects induced by clopidogrel on platelet procoagulant activity in type 2 diabetes mellitus patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003792538

Thromboxane biosynthesis and platelet function in type II diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003792538

The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003792538

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003792538

Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003792538

AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003792538

Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003792538

Standards of medical care in diabetes--2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003792538

Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A Scientific Statement From the American Heart Association and the American Diabetes Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003792538

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003792538

A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003792538

Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003792538

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003792538

Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003792538

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003792538

Effect of a multifactorial intervention on mortality in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003792538

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003792538

Prevalence of aspirin resistance in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003792538

Blood platelet reactivity and its pharmacological modulation in (people with) diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003792538

Aspirin resistance: position paper of the Working Group on Aspirin Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003792538

Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003792538

Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003792538

Increased basal platelet activity, plasma adiponectin levels, and diabetes mellitus are associated with poor platelet responsiveness to in vitro effect of aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003792538

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003792538

10.1517/14656561003792538

21 January 2018

Identifiers

DOI

1 reference

13 November 2017

1 reference